GLPG:NASDAQGalapagos NV Analysis

Technical outlook: GLPG trades at $27.73, sitting just below its 20‑day SMA ($27.80) and well under the 50‑day ($28.24) and 200‑day ($31.57) averages, confirming a bearish trend. The RSI of 58 signals modest momentum, while the MACD histogram is positive (0.20) and the signal line is bullish, suggesting a potential short‑term rebound. Volume is increasing and the stock is defending a support level around $26.42, with resistance near $29.07. Volatility remains high at ~30% over the past 30 days, though beta is modest at 0.76, indicating less market‑wide sensitivity.
Fundamental backdrop: The company appears dramatically undervalued with a trailing P/E of 3.2 versus an industry average of 24.3, a price‑to‑book of 9.6, and a DCF fair value estimate of $86. Cash sits at $2.98 B against negligible debt, and free cash flow is positive $211 M. However, revenue has collapsed by 91% and operating margins are negative, underscoring execution risk. The pipeline of oncology and immunology candidates and a recent 5% institutional stake by Bank of America add a speculative growth catalyst.